IQ-AI Limited (GB:IQAI) has released an update.
IQ-AI Limited reports a 57% increase in first-half revenue to £444,000 and a rise in net assets to £433,188, showing significant progress with their Phase 1 Clinical Trial for gallium maltolate and advancements in their IB Clinic software. They’re on track to introduce new features, enhancements, and AI capabilities, aiming to revolutionize medical imaging and analysis with their diversified product portfolio.
For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.
